Neonatal administration of thimerosal causes persistent changes in mu opioid receptors in the rat brain.
Thimerosal added to some pediatric vaccines is suspected in pathogenesis of several neurodevelopmental disorders. Our previous study showed that thimerosal administered to suckling rats causes persistent, endogenous opioid-mediated hypoalgesia. Here we examined, using immunohistochemical staining technique, the density of μ-opioid receptors (MORs) in the brains of rats, which in the second postnatal week received four i.m. injections of thimerosal at doses 12, 240, 1,440 or 3,000 μg Hg/kg. The periaqueductal gray, caudate putamen and hippocampus were examined. Thimerosal administration caused dose-dependent statistically significant increase in MOR densities in the periaqueductal gray and caudate putamen, but decrease in the dentate gyrus, where it was accompanied by the presence of degenerating neurons and loss of synaptic vesicle marker (synaptophysin). These data document that exposure to thimerosal during early postnatal life produces lasting alterations in the densities of brain opioid receptors along with other neuropathological changes, which may disturb brain development.
Olczak
Mieszko
M
Department of Pharmacology and Physiology of the Nervous System, Institute of Psychiatry and Neurology, Warsaw, Poland.
Duszczyk
Michalina
M
Mierzejewski
Pawel
P
Bobrowicz
Teresa
T
Majewska
Maria Dorota
MD
D000818:Animals; D000831:Animals, Newborn; D001921:Brain / Q000187:drug effects / Q000254:growth & development; D051381:Rats; D017208:Rats, Wistar; D017450:Receptors, Opioid, mu / Q000187:drug effects* / Q000378:metabolism*; D016708:Synaptophysin / Q000378:metabolism; D013849:Thimerosal / Q000494:pharmacology*
D017450:Receptors, Opioid, mu; D016708:Synaptophysin; D013849:Thimerosal
J Comp Neurol. 2005 Dec 5;493(1):2-8
16255004
Mol Pharmacol. 2004 Dec;66(6):1719-26
15448191
J Neurosci Methods. 1980 Dec;3(2):129-49
6110810
Toxicol Sci. 2009 Aug;110(2):389-400
19465457
Environ Res. 1997;74(1):48-53
9339214
Int J Mol Med. 2005 Dec;16(6):971-7
16273274
J Pharmacol Exp Ther. 2000 Apr;293(1):113-20
10734160
Folia Neuropathol. 1998;36(1):15-23
9595859
Altern Ther Health Med. 2009 Mar-Apr;15(2):56-60
19284184
Proc Natl Acad Sci U S A. 1984 Jun;81(12):3893-7
6328530
Mol Psychiatry. 2004 Sep;9(9):833-45
15184908
Ann Neurol. 1978 Nov;4(5):451-62
216303
Brain Res. 1983 Apr;283(2-3):157-69
6303517
Toxicol Sci. 2007 Jan;95(1):156-62
17047031
Anal Chem. 2003 Aug 15;75(16):4120-4
14632125
Neuro Endocrinol Lett. 2005 Oct;26(5):439-46
16264412
Cancer Res. 2004 Jul 15;64(14):4919-26
15256464
Acta Neurobiol Exp (Wars). 2010;70(2):196-208
20628443
Receptor. 1992 Summer;2(2):109-19
1335327
J Pediatr. 2000 May;136(5):679-81
10802503
Neuropharmacology. 1990 May;29(5):445-52
2162496
Brain Res. 1985 Dec 23;360(1-2):117-29
3000529
Pediatrics. 2008 Feb;121(2):e208-14
18245396
Brain Res. 2009 Dec 8;1301:143-51
19747466
Eur J Pharmacol. 1988 Oct 26;156(1):47-54
2850210
J Neurosci. 1997 Jan 1;17(1):477-92
8987772
Med Hypotheses. 2001 Apr;56(4):462-71
11339848
Toxicol Appl Pharmacol. 2005 Oct 1;208(1):21-8
16164958
Synapse. 1988;2(3):193-9
2463689
Br J Pharmacol. 1978 Jun;63(2):303-8
208703
J Neurol Sci. 2008 Aug 15;271(1-2):110-8
18482737
Prog Brain Res. 2007;163:245-63
17765723
Exp Biol Med (Maywood). 2003 Jun;228(6):660-4
12773696
Proc Natl Acad Sci U S A. 1980 Sep;77(9):5532-6
6254088
Toxicol Appl Pharmacol. 2005 Apr 15;204(2):109-21
15808517
Med Hypotheses. 1986 Jan;19(1):41-5
3010057
Arch Toxicol. 1985 Sep;57(4):260-7
4091651
Int J Toxicol. 2003 Jul-Aug;22(4):277-85
12933322
Pharmacol Rev. 2004 Sep;56(3):351-69
15317908
Mol Psychiatry. 2004 Apr;9(4):358-70
14745455
Brain Dev. 2005 Oct;27(7):509-16
16198209
Mol Pharmacol. 2007 Jan;71(1):123-31
17005904